Ashish Kulkarni

Ashish Kulkarni

Auto-generated profile, based on publicly available information

Ashish Kulkarni

Department of Chemical Engineering University of Massachusetts Amherst MA 01003 USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2018 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
AKAshish Kulkarni
Ashish Kulkarni
VCVineethkrishna Chandrasekar
Vineethkrishna Chandrasekar
SNSiva Kumar Natarajan
Siva Kumar Natarajan
ARAnujan Ramesh
Anujan Ramesh
PPPrithvi Pandey
Prithvi Pandey
SSShiladitya Sengupta
Shiladitya Sengupta

29 October 2019 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
ARAnujan Ramesh
Anujan Ramesh
SKSahana Kumar
Sahana Kumar
DNDipika Nandi
Dipika Nandi
AKAshish Kulkarni
Ashish Kulkarni

25 June 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PSPoulomi Sengupta
Poulomi Sengupta
SBSudipta Basu
Sudipta Basu
SSShivani Soni
Shivani Soni
APAmbarish Pandey
Ambarish Pandey
BRBhaskar Roy
Bhaskar Roy
SSShiladitya Sengupta
Shiladitya Sengupta
Nanoscale drug delivery vehicles have been harnessed extensively as carriers for cancer chemotherapeutics. However, traditional pharmaceutical approaches for nanoformulation have been a challenge with molecules that exhibit incompatible physicochemical properties, such as platinum-based chemotherapeutics. Here we propose a paradigm based on rational design of active molecules that facilitate supramolecular assembly in the nanoscale dimension. Using cisplatin as a template, we describe the synthesis of a unique platinum (II) tethered to a cholesterol backbone via a unique monocarboxylato and O→Pt coordination environment that facilitates nanoparticle assembly with a fixed ratio of phosphatidylcholine and 1,2-distearoyl- sn -glycero-3-phosphoethanolamine- N -[amino (polyethylene glycol)-2000]. The nanoparticles formed exhibit lower IC 50 values compared with carboplatin or cisplatin in vitro, and are active in cisplatin-resistant conditions. Additionally, the nanoparticles exhibit significantly enhanced in vivo antitumor efficacy in murine 4T1 breast cancer and in K-Ras LSL/+ /Pten fl/fl ovarian cancer models with decreased systemic- and nephro-toxicity. Our results indicate that integrating rational drug design and supramolecular nanochemistry can emerge as a powerful strategy for drug development. Furthermore, given that platinum-based chemotherapeutics form the frontline therapy for a broad range of cancers, the increased efficacy and toxicity profile indicate the constructed nanostructure could translate into a next-generation platinum-based agent in the clinics.

11 May 2020 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
ARAnujan Ramesh
Anujan Ramesh
SKSahana Kumar
Sahana Kumar
ABAnthony Brouillard
Anthony Brouillard
DNDipika Nandi
Dipika Nandi
AKAshish Kulkarni
Ashish Kulkarni

19 October 2019 in Biomaterials
Verified
Journal Article
Closed access
ARAnujan Ramesh
Anujan Ramesh
ABAnthony Brouillard
Anthony Brouillard
SKSahana Kumar
Sahana Kumar
DNDipika Nandi
Dipika Nandi
AKAshish Kulkarni
Ashish Kulkarni

1 August 2017 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
HPHardik J. Pandya
Hardik J. Pandya
KDKaran Dhingra
Karan Dhingra
DPDevbalaji Prabhakar
Devbalaji Prabhakar
VCVineethkrishna Chandrasekar
Vineethkrishna Chandrasekar
SNSiva Kumar Natarajan
Siva Kumar Natarajan
HSHadi Shafiee
Hadi Shafiee